1. Home
  2. CGEM vs HLF Comparison

CGEM vs HLF Comparison

Compare CGEM & HLF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$20.77

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Herbalife Ltd.

HLF

Herbalife Ltd.

HOLD

Current Price

$11.94

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEM
HLF
Founded
2016
1980
Country
United States
United States
Employees
109
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Pharmaceuticals
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
2020
2004

Fundamental Metrics

Financial Performance
Metric
CGEM
HLF
Price
$20.77
$11.94
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
5
Target Price
$30.13
$18.00
AVG Volume (30 Days)
750.3K
1.6M
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.33
Revenue
N/A
$5,037,500,000.00
Revenue This Year
N/A
$4.97
Revenue Next Year
$5.20
$3.80
P/E Ratio
N/A
$35.42
Revenue Growth
N/A
0.89
52 Week Low
$5.68
$7.56
52 Week High
$23.19
$20.40

Technical Indicators

Market Signals
Indicator
CGEM
HLF
Relative Strength Index (RSI) 49.46 46.64
Support Level $11.87 $11.37
Resistance Level $23.19 $13.09
Average True Range (ATR) 0.96 0.58
MACD -0.26 -0.04
Stochastic Oscillator 51.40 53.62

Price Performance

Historical Comparison
CGEM
HLF

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

About HLF Herbalife Ltd.

Herbalife Ltd is a health and wellness company. It provides health and wellness products in 95 markets through a direct-selling business model. Its product categories include Weight Management, Targeted Nutrition, Energy, Sports and Fitness, Outer Nutrition, and Literature, Promotional, and Other. Weight Management generates the majority of revenue, with products such as meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Products are manufactured at facilities in Changsha and Suzhou, China; Lake Forest, California; and Winston-Salem, North Carolina, as well as by third-party providers. Revenues reflect sales to Members across North America, Latin America, EMEA, Asia Pacific, and China.

Share on Social Networks: